LIGACHEM BIOSCIENCES INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 63,700 KRW | -0.93% |
|
-5.91% | -2.00% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -2.00% | 1.66B | - | ||
| +11.91% | 118B | B+ | ||
| +11.60% | 106B | B+ | ||
| -4.68% | 24.28B | B+ | ||
| -0.82% | 21.96B | B | ||
| -10.12% | 18.16B | A- | ||
| -42.12% | 16.37B | A- | ||
| -17.47% | 15.56B | B | ||
| +2.77% | 13.63B | C+ | ||
| +34.58% | 12.27B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- A141080 Stock
- Ratings LigaChem Biosciences Inc.
